Navigation Links
Computational model simulates AZT metabolism in mitochondria

Researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech have developed a computational model that allows scientists to better understand the metabolism and toxicity of the HIV/AIDS drug zidovudine (azidothymidine, AZT).

AZT is used successfully as part of Highly Active Anti-Retroviral Therapy (HAART) to control the level of the human immunodeficiency virus in HIV-infected individuals. However, long-term use of AZT may lead to side-effects in some patients. David Samuels and coworkers are interested in finding out whether the toxic side effects of AZT can eventually be minimized or even eliminated. For this purpose, they have been developing a detailed computational model that allows scientists to simulate the biochemical reactions that take place when AZT is metabolized in cells, including their mitochondria, under different metabolic conditions. Drugs like AZT may interfere with DNA replication in the mitochondria, the energy factories of our cells, and can lead to potentially fatal side effects in patients undergoing HAART treatment.

Samuels, assistant professor at VBI, commented: "HAART is one of the biggest success stories in modern medicine. The goal of our work is to help improve this successful treatment by understanding the toxic effects that AZT can have in some people. There are many different ways that AZT could possibly interfere with mitochondria to cause the toxic side-effects. Our job is to model these proposed toxicity mechanisms to see which ones could actually lead to the mitochondrial defects found in AIDS patients." He added: "It is possible that no single mechanism is responsible for the toxicity, but that instead a combination of multiple effects is needed. That is the kind of problem that needs a systems biology approach."

When AZT reaches a cell, it is subject to some of the same metabolic modifications or phosphorylation events that are encountered by the four naturally occurring deoxynucleos ides, the building blocks used to make DNA. However, modified AZT molecules lack a specific chemical group (a hydroxyl group) that would allow DNA replication to continue. This results in premature termination of DNA synthesis. It is thought that the triphosphorylated form of AZT can enter the mitochondrial matrix, the inner core of the mitochondrion, and disrupt the replication of mitochondrial DNA by prematurely terminating DNA synthesis.

Samuels added: "We're just starting our work. It is too early to say what the mechanism of mitochondrial toxicity of AZT is. The inhibition of deoxynucleoside metabolism is one possibility. The incorporation of AZT into mitochondrial DNA is another." He added: "The detailed computational model that we have developed should allow researchers to explore different hypotheses as to why AZT can lead to such debilitating side effects in some patients undergoing anti-retroviral treatment."


'"/>

Source:Virginia Tech


Related biology news :

1. Supercomputer Dedicated To Bioengineering, Computational Biology Installed
2. Institute for Systems Biology Symposium Addresses Need for Better Computational Tools
3. Computational Method Speeds Mapping of Cell Signaling Networks
4. Computational verification of protein-protein interactions by orthologous co-expression
5. Computational Tool Predicts How Drugs Work In Cells, Advancing Efforts To Design Better Medicines
6. Computational analysis shows that plant hormones often go it alone
7. Scientists identify new model Of NK cell development
8. Genrate: a generative model that finds and scores new genes and exons in genomic microarray data
9. Molecular models advance the fight against malaria
10. NYU and MSKCC research provides model for understanding chemically induced cancer initiation
11. Genetic therapy reverses nervous system damage in animal model of inherited human disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/7/2018)... (PRWEB) , ... November 07, 2018 , ... ... unified communications and collaboration solutions, announced today a modernized and streamlined White Label ... website and a newly established reseller administrative control portal. CallTower enhanced their ...
(Date:11/6/2018)... ... November 06, 2018 , ... Genedata, a leading provider of ... a subsidiary of Sartorius Stedim Biotech (SSB) and a specialist for cell line ... Bioprocess ® enterprise platform to be used at SSB laboratories in Germany, the ...
(Date:11/3/2018)... (PRWEB) , ... November 01, 2018 , ... As 2018 ... (EU) continue to alter the landscape of quality systems for manufacturers worldwide. To mark ... device makers must act on now. , “While 2020 may sound far off, the ...
Breaking Biology News(10 mins):
(Date:10/31/2018)... ... October 30, 2018 , ... Rooam , the premier ... in Chicago this winter. After its acquisition of the Tally payment app, the leading ... set default tips, Rooam will grow its market share and increase the number of ...
(Date:10/29/2018)... ... October 29, 2018 , ... PracticeMatch , a company ... its schedule of physician career fairs planned for 2019. The company has expanded its ... live events in the areas of the country which have the highest concentrations of ...
(Date:10/24/2018)... ... October 23, 2018 , ... Molecular ... new, exciting brand for its recently created biologics solutions business unit. The business ... portfolio of products, and henceforth will be known as ForteBio. It is accompanied ...
(Date:10/17/2018)... ... October 17, 2018 , ... ... development solutions for drugs, biologics and consumer health products, today announced that Cornell ... Institute, will present at the annual Partnership Opportunities in Drug Delivery (PODD) meeting ...
Breaking Biology Technology: